Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: Interphase cytogenetic detection of BCR-ABL-positive lesional cells

Archives of Dermatology

Volumn 144, Issue 3, 2008, Pages 361-364

  Kaune, Kjell Matthias ^a   Baumgart, Mario ^a   Gesk, Stefan ^b   Mitteldorf, Christina ^a   Baesecke, Joerg ^a   Glass, Bertram ^a   Haase, Detlef ^a   Siebert, Reiner ^b   Ghadimi, B Michael ^a   Neumann, Christine ^a   Emmert, Steffen ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; IMATINIB; MEROPENEM; NILOTINIB; PREDNISOLONE; VANCOMYCIN;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; AGED; ARTICLE; BULLOUS SWEET SYNDROME; CASE REPORT; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LUNG LAVAGE; MALE; MYCOSIS; NEUTROPHIL; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; SKIN BIOPSY; THORAX RADIOGRAPHY; VIRUS INFECTION;

AGED; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SWEET'S SYNDROME;

EID: 41149169716     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.3.361     Document Type: Article

References (25)

1. Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964;76:349-356.
2. Cohen PR, Kurzrock R. Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol. 2003;42(10):761-778.
3. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-566.
4. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94(12):1765-1769.
5. Lim TH, Tien SL, Lim P, Lim AS. The incidence and patterns of BCR/ABL rearrangements in chronic myeloid leukaemia (CML) using fluorescence in situ hybridisation (FISH). Ann Acad Med Singapore. 2005;34(9):533-538.
6. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006;8(2):141-151.
7. Cohen PR, Kurzrock R. Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol. 2000;18(3):265-282.
8. Fitzgerald RL, McBurney EI, Nesbitt LT Jr. Sweet's syndrome. Int J Dermatol. 1996;35(1):9-15.
9. Bello López JL, Fonseca E, Manso F. Sweet's syndrome during the chronic phase of chronic myeloid leukaemia. Acta Haematol. 1990;84(4):207-208.
10. Fernández-Jiménez MC, Herraez R, Ojeda E, Hernandez-Navarro F. Sweet's syndrome and accelerated phase of chronic myelogenous leukemia. Ann Hematol. 2000;79(10):585-587.
11. Voelter-Mahlknecht S, Bauer J, Metzler G, Fierlbeck G, Rassner G. Bullous variant of Sweet's syndrome. Int J Dermatol. 2005;44(11):946-947.
12. Salmon-Ehr V, Esteve E, Serpier H, Cambie MP, Pignon B, Kalis B. Acute febrile pustular and bullous neutrophilic dermatosis (Sweet syndrome) disclosing acute myeloblastic leukemia. Rev Med Interne. 1995;16(5):347-350.
13. Chiang CT, Chan HL, Kuo TT, Wang PN. Herpes zoster-like Sweet's syndrome in acute myelogenous leukemia. Int J Dermatol. 1997;36(9):717-718.
14. Kannan R, Dutta TK, Goel A, Garg BR, Venkateswaran S, Ratnakar C. Sweet syndrome in chronic myeloid leukaemia [letter]. Postgrad Med J. 1995;71(836):383.
15. Visani G, Patrizi AL, Ricci P, et al. Sweet's syndrome: association with accelerated phase of chronic myeloid leukemia. Acta Haematol. 1988;79(4):207-210.
16. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature. 1973;243(5405):290-293.
17. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247(4946):1079-1082.
18. Ayirookuzhi SJ, Ma L, Ramshesh P, Mills G. Imatinib-induced Sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol. 2005;141(3):368-370.
19. Liu D, Seiter K, Mathews T, Madahar CJ, Ahmed T. Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking imatinib mesylate. Leuk Res. 2004;28(suppl 1):S61-S63.
20. Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica. 2005;90(4):534-541.
21. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542-2551.
22. Urano Y, Miyaoka Y, Kosaka M, Kabe K, Uchida N, Arase S. Sweet's syndrome associated with chronic myelogenous leukemia: demonstration of leukemic cells within a skin lesion. J Am Acad Dermatol. 1999;40(2, pt 1):275-279.
23. Tomasini C, Aloi F, Osella-Abate S, Dapavo P, Pippione M. Immature myeloid precursors in chronic neutrophilic dermatosis associated with myelodysplastic syndrome. Am J Dermatopathol. 2000;22(5):429-433.
24. Magro CM, De ME, Burns F. Sweet's syndrome in the setting of CD34-positive acute myelogenous leukemia treated with granulocyte colony stimulating factor: evidence for a clonal neutrophilic dermatosis. J Cutan Pathol. 2001;28(2):90-96.
25. Watari K, Tojo A, Nagamura-Inoue T, et al. Hyperfunction of neutrophils in a patient with BCR/ABL negative chronic myeloid leukemia: a case report with in vitro studies. Cancer. 2000;89(3):551-560.